These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 19073502

  • 1. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
    Yardley DA.
    Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
    [Abstract] [Full Text] [Related]

  • 2. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
    Vahdat L.
    Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
    [Abstract] [Full Text] [Related]

  • 3. Ixabepilone, a new treatment option for metastatic breast cancer.
    Toppmeyer DL, Goodin S.
    Am J Clin Oncol; 2010 Oct; 33(5):516-21. PubMed ID: 20023567
    [Abstract] [Full Text] [Related]

  • 4. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
    Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH.
    Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
    [Abstract] [Full Text] [Related]

  • 5. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
    Boehnke Michaud L.
    J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
    [Abstract] [Full Text] [Related]

  • 6. Ixabepilone for the treatment of breast cancer.
    Alvarez RH, Valero V, Hortobagyi GN.
    Ann Med; 2011 Jun; 43(6):477-86. PubMed ID: 21585248
    [Abstract] [Full Text] [Related]

  • 7. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
    Rivera E, Lee J, Davies A.
    Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
    [Abstract] [Full Text] [Related]

  • 8. Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.
    Fornier M.
    Clin Breast Cancer; 2010 Oct 01; 10(5):352-8. PubMed ID: 20920979
    [Abstract] [Full Text] [Related]

  • 9. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, Vite G.
    Cancer Chemother Pharmacol; 2008 Dec 01; 63(1):157-66. PubMed ID: 18347795
    [Abstract] [Full Text] [Related]

  • 10. Application of epothilones in breast cancer therapy.
    Cianfrocca M.
    Curr Opin Oncol; 2008 Nov 01; 20(6):634-8. PubMed ID: 18841044
    [Abstract] [Full Text] [Related]

  • 11. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer.
    Perez EA.
    Breast Cancer Res Treat; 2009 Mar 01; 114(2):195-201. PubMed ID: 18443902
    [Abstract] [Full Text] [Related]

  • 12. Ixabepilone: clinical role in metastatic breast cancer.
    Denduluri N, Swain S.
    Clin Breast Cancer; 2011 Jun 01; 11(3):139-45. PubMed ID: 21665133
    [Abstract] [Full Text] [Related]

  • 13. Clinical studies with epothilones for the treatment of metastatic breast cancer.
    Vahdat LT.
    Semin Oncol; 2008 Apr 01; 35(2 Suppl 2):S22-30; quiz S40. PubMed ID: 18410796
    [Abstract] [Full Text] [Related]

  • 14. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF, Lee FY, Canetta RM.
    Anticancer Drugs; 2014 May 01; 25(5):599-609. PubMed ID: 24398663
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
    Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Cai C, Mullaney B, Peck R, Hortobagyi GN.
    J Clin Oncol; 2007 Aug 10; 25(23):3407-14. PubMed ID: 17606974
    [Abstract] [Full Text] [Related]

  • 16. Current perspectives of epothilones in breast cancer.
    Cardoso F, de Azambuja E, Lago LD.
    Eur J Cancer; 2008 Feb 10; 44(3):341-52. PubMed ID: 18178426
    [Abstract] [Full Text] [Related]

  • 17. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M.
    Clin Ther; 2008 Sep 10; 30(9):1590-617. PubMed ID: 18840366
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer.
    De Luca A, D'Alessio A, Maiello MR, Gallo M, Chicchinelli N, Pergameno M, Piccirilli MS, Normanno N.
    Expert Opin Drug Metab Toxicol; 2015 Jul 10; 11(7):1177-85. PubMed ID: 26073581
    [Abstract] [Full Text] [Related]

  • 19. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA.
    Pharmacotherapy; 2008 Oct 10; 28(10):1255-66. PubMed ID: 18823221
    [Abstract] [Full Text] [Related]

  • 20. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
    Thomas ES.
    J Clin Oncol; 2008 May 01; 26(13):2223. PubMed ID: 18445853
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.